Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million
Published on: Tuesday 18 January 2022
REYKJAVIK, Iceland, January 18, 2022--Alvotech Holdings S.A. ("Alvotech"), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II ("Oaktree II") (NYSE: OACB), a publicly traded special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P., today announced $21 million in additional commitments for a private placement ("PIPE") of Oaktree II comm
RELATED NEWS
